Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 15/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 14/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 14/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 14/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 14/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 14/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | NR2E1 | Q9Y466 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13361926 | 0.84 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7799638 | 0.82 | NR2E1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3329200 | 0.81 | NR2E1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3322146 | 0.79 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13361924 | 0.79 | PSEN1 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7846890 | 0.70 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12361914 | 0.70 | NR2E1 (0.64) | NR2E1 | |
| SCHEMBL3433422 | 0.69 | PSEN1 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4107745 | 0.69 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8817444 | 0.69 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | PDE2A, PDE5A, PDE3A | PSEN1 3784/4885PSEN2 4041/4885APH1B 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.